A Smart + Strong Site
Subscribe to:
POZ magazine
AIDS viruslersivirine belongs to a class of anti-HIV drugs called Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.

Lersivirine is being developed by ViiV Healthcare. They have a useful web site that includes the latest news & research reports on this drug: click here.

AIDS drugs chartOur quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
news Treatment News
Search for recent news and archived stories about lersivirine.
forumsHave more questions? Then post a question or comment in our Community Forums.
Help Paying for MedsHelp Paying for Meds: Patient assistance and co-pay programs for HIV and viral hepatitis drugs.
Lessons Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
Collapse All

Recommended Reading List:

Books about AIDS & HIV treatmentsFor a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from Amazon.com, click here.

Lersivirine (UK-453061)

Pronunciation(s): ler-SIV-arine

What is the most important information I should know about lersivirine?
What is lersivirine?
  • Lersivirine is in a category of HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). lersivirine prevents HIV from entering the nucleus of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
  • Lersivirine will need to be used in combination with other drugs. Clinical trials will evaluate its effect in combination with other drugs, including nucleoside reverse transcriptase inhibitors (NRTIs).

What is already known about lersivirine?
  • The correct dose for lersivirine has not yet been determined. Preliminary experiments suggest that the drug can be taken by mouth once a day.
  • Like other NNRTIs, lersivirine might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
  • It is expected that lersivirine, when combined with other HIV medications, will have strong activity against HIV in people who have never taken an NNRTI in the past. A Phase I study, testing once- and twice-daily dosing of the drug as monotherapy (not in combination with other HIV medications), found that lersivirine has potent antiviral activity after a seven-day course of treatment. A phase II study, comparing lersivirine with Sustiva (efavirenz) in combination with other HIV medications, is currently under way.
  • It is not yet known if lersivirine will work against strains of HIV that are already resistant to currently available NNRTIs.

What about drug interactions?
  • There have not yet been studies demonstrating which other drugs may interact with lersivirine. Studies to help determine this are planned or ongoing.

What is known about side effects?
  • Little is known about lersivirine's side effect profile. It was well tolerated in the seven-day Phase I study reported to date.

Who should not take lersivirine?
  • It is not known whether lersivirine will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
  • It is not known whether lersivirine passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.

Where can I learn more about clinical trials of lersivirine?
  • If you would like to find out if you are eligible for any clinical trials that include lersivirine, visit ClinicalTrials.gov, a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email contactus@aidsinfo.nih.gov.

Last Revised: September 28, 2010

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.